Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response.

OBJECTIVE Regulatory T lymphocytes (Tregs) probably play an important role in the pathogenesis of SLE. METHODS We quantified messenger RNA (mRNA) expression of FOXP3, a critical regulator for the development and function of Tregs, in the urinary sediment of 25 subjects with active lupus nephritis (LN), 17 with inactive lupus and 7 healthy subjects. RESULTS We found that the expression level of FOXP3 was significantly higher in urine from patients with active LN than from subjects with inactive lupus and healthy controls (24.5 +/- 45.8 vs 0.8 +/- 1.0 vs 0.6 +/- 0.8 copy; P < 0.001). In the active group, urinary FOXP3 mRNA expression level was higher in patients with proliferative LN than non-proliferative nephritis (34.6 +/- 56.3 vs 2.7 +/- 2.1 copy; P = 0.019). Urinary FOXP3 mRNA level significantly correlated with SLEDAI (r = 0.668; P < 0.001) and proteinuria (r = 0.414; P = 0.006). In the active group, urinary FOXP3 mRNA level also significantly correlated with histological activity index (r = 0.541; P = 0.009) and marginally with intra-renal FOXP3 mRNA level (r = 0.360; P = 0.08). Urinary FOXP3 mRNA in patients with no response to therapy was higher than those with partial response or complete response (57.6 +/- 69.8 vs 2.4 +/- 1.9 copies; P = 0.02). CONCLUSION We concluded that urinary FOXP3 mRNA is markedly up-regulated in patients with active LN, and the level of expression is closely correlated with the clinical and histological disease activity. A high urinary FOXP3 mRNA in LN predicts a poor therapeutic response. Measurement of FOXP3 mRNA in urine sediment may be a non-invasive biomarker for assessing the severity and risk stratification in LN.

[1]  J. Smolen,et al.  Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis , 2007, Annals of the rheumatic diseases.

[2]  C. Putterman,et al.  Lipocalin‐2, TWEAK, and Other Cytokines as Urinary Biomarkers for Lupus Nephritis , 2007, Annals of the New York Academy of Sciences.

[3]  R. Colvin,et al.  Pathological and Clinical Correlates of FOXP3+ Cells in Renal Allografts during Acute Rejection , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  F. Lai,et al.  Intrarenal cytokine gene expression in lupus nephritis , 2007, Annals of the Rheumatic Diseases.

[5]  P. Lipsky,et al.  Deficient CD4+CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus1 , 2007, The Journal of Immunology.

[6]  J. Stockman.  Messenger RNA for FOXP3 in the Urine of Renal-Allograft Recipients , 2007 .

[7]  A. Torgashina,et al.  Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. , 2007, Advances in experimental medicine and biology.

[8]  A. Banham,et al.  FOXP3+ regulatory T cells: Current controversies and future perspectives , 2006, European journal of immunology.

[9]  G. Appel,et al.  Update on the treatment of lupus nephritis. , 2006, Kidney international.

[10]  R. González-Amaro,et al.  Regulatory T cells in patients with systemic lupus erythematosus. , 2006, Journal of autoimmunity.

[11]  F. Lai,et al.  The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  F. Lai,et al.  Urinary mononuclear cell and disease activity of systemic lupus erythematosus , 2006, Lupus.

[13]  S. Ziegler.  FOXP3: of mice and men. , 2006, Annual review of immunology.

[14]  Yao-Hsu Yang,et al.  Inverse correlation between CD4+ regulatory T‐cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus , 2006, Immunology.

[15]  P. Debré,et al.  Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus1 , 2005, The Journal of Immunology.

[16]  D. Jayne,et al.  Diagnosis and treatment of kidney disease. , 2005, Best practice & research. Clinical rheumatology.

[17]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[18]  M. Schilham,et al.  Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. , 2005, Human immunology.

[19]  D. Levison,et al.  Renal biopsy , 2005, The Histochemical Journal.

[20]  F. Lai,et al.  Messenger RNA expression of target genes in the urinary sediment of patients with chronic kidney diseases. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  F. Lai,et al.  Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. , 2004, Arthritis and rheumatism.

[22]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.

[23]  S. Ziegler,et al.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. , 2003, The Journal of clinical investigation.

[24]  J. Alcocer-Varela,et al.  Quantification of regulatory T cells in patients with systemic lupus erythematosus. , 2003, Journal of autoimmunity.

[25]  F. Lai,et al.  Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. , 2003, Arthritis and rheumatism.

[26]  C. Fiehn,et al.  Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment , 2003, Annals of the rheumatic diseases.

[27]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[28]  D. Heudes,et al.  Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  M. Suthanthiran,et al.  Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. , 2001, The New England journal of medicine.

[30]  T. Chan,et al.  Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis , 2000 .

[31]  C. Lau,et al.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. , 2000, The New England journal of medicine.

[32]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[33]  J. Grande,et al.  Renal biopsy in lupus nephritis , 1998, Lupus.

[34]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[35]  K. Matsushima,et al.  Detection of urinary interleukin-8 in glomerular diseases. , 1994, Kidney international.

[36]  H. Claman,et al.  Immunological tolerance to self and non-self. , 1982, Annals of the New York Academy of Sciences.

[37]  A D GUNN,et al.  Case of Anaphylaxis after Anaesthesia , 1943, British medical journal.